Consensus $44.98M. Narrows FY25 adjusted EBITDA loss view to $47M-$51M from $46M-$53M.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AQST:
- Aquestive Therapeutics options imply 14.6% move in share price post-earnings
- Aquestive appoints Davis as CDO, Slatko as interim CMO, Boyd as CPO
- Aquestive Therapeutics price target raised to $12 from $9 at Citizens JMP
- Aquestive Therapeutics Secures New Patents for Anaphylm
- Aquestive Therapeutics issued two additional U.S. patents to Anaphylm